Sign in to continue:

Wednesday, March 25th, 2026

ParkerVision, Inc. 8-K Filing March 2026: Financial Statements, Address, and SEC Entity Information

ParkerVision, Inc. Reports 2025 Financial Results and Corporate Updates

JACKSONVILLE, FL, March 23, 2026 – ParkerVision, Inc. (OTCQB: PRKR), a company engaged in the development and licensing of radio-frequency (RF) technologies, has released its annual financial results for the year ended December 31, 2025, alongside key corporate updates that may hold significant implications for shareholders and potential investors.

Key Highlights from the 2025 Financial Report

  • Substantial Reduction in Net Loss: ParkerVision reported a net loss of \$7.4 million for the year 2025, a marked improvement from the net loss of \$14.5 million in 2024. This reduction was reflected in the per-share loss, which decreased from \$0.16 in 2024 to \$0.06 in 2025.
  • Share-Based Compensation Expense Surge: Share-based compensation expense increased by \$3.0 million year-over-year, primarily due to a one-time noncash charge of \$2.5 million recognized in 2025. This charge resulted from the modification of previously issued, fully vested nonqualified share options held by executives and key employees, extending their expiration date from January 2026 to January 2031, while maintaining the exercise price of \$0.54 per share.
  • Strong Liquidity Position: ParkerVision ended 2025 with \$4.4 million in cash and cash equivalents, and approximately \$2.3 million in working capital, indicating a solid liquidity buffer to support ongoing operations and legal proceedings.
  • Capital Raises:
    • In November 2025, the company completed a direct offering of 21.2 million shares at \$0.21 per share, raising gross proceeds of approximately \$4.5 million.
    • In March 2026, ParkerVision issued another 3.2 million shares at \$0.21 per share to satisfy \$0.67 million in upcoming convertible note maturities, thus preserving cash and strengthening working capital.

Balance Sheet Highlights (as of December 31, 2025)

Item 2025 (in \$000s) 2024 (in \$000s)
Cash and cash equivalents 4,360 4,918
Prepaid expenses and other current assets 304 127
Intangible assets & noncurrent assets 695 834
Total assets 5,359 5,879
Convertible notes, net of current portion 1,908 2,052
Other long-term liabilities 57 201
Shareholders’ deficit (45,104) (46,412)
Total liabilities and shareholders’ deficit 5,359 5,879

Summary of Operations (Year Ended December 31)

Item 2025 (in \$000s) 2024 (in \$000s)
Licensing revenue
Cost of sales (199) (229)
Gross margin (199) (229)
Selling, general and administrative expenses 7,606 4,262
Total operating expenses 7,606 4,262
Change in fair value of contingent payment obligations 570 (9,639)
Total other income (expense) 379 (9,639)
Net loss (7,426) (14,507)
Basic and diluted net loss per share (0.06) (0.16)

Cash Flow Highlights (Year Ended December 31)

Item 2025 (in \$000s) 2024 (in \$000s)
Net cash used in operating activities (5,143) (3,216)
Net cash used in investing activities (61)
Net cash provided by financing activities 4,646 5,574
Net decrease in cash and cash equivalents (558) 2,358
Cash and cash equivalents – end of period 4,360 4,918

Other Notable Items for Investors

  • Shareholder Dilution Events: The company issued a significant number of shares in both November 2025 and March 2026, which may impact existing shareholders through dilution but have bolstered liquidity and addressed upcoming debt maturities.
  • Legal and Regulatory Risks: The company continues to highlight the risks associated with ongoing legal proceedings, including the timing and outcome of court and PTAB (Patent Trial and Appeal Board) rulings. Adverse outcomes or delays could materially impact the company’s financial position and future prospects.
  • Forward-Looking Statements and Risks: ParkerVision cautions investors that its forward-looking statements are subject to significant risks and uncertainties, including but not limited to adverse legal developments, changes in the regulatory environment, loss of key witnesses, funding availability, and inaccuracies in financial estimates. Investors are strongly advised to review the company’s filings, including the Annual Report on Form 10-K for the year ended December 31, 2025, for a comprehensive risk assessment.

What Investors Should Watch

  • A substantial reduction in net loss year-over-year may signal improving operational efficiency or cost management.
  • The significant increase in share-based compensation and option modification for key executives could be a double-edged sword, aligning management interests but also raising concerns about dilution and non-cash charges.
  • Recent capital raises and debt conversion transactions have improved liquidity but have diluted existing shareholders. The company’s ability to maintain its cash position and manage maturities will be crucial.
  • No revenue was recorded from licensing in 2024 or 2025, emphasizing the company’s reliance on financing activities and the need for successful litigation or licensing outcomes to drive top-line growth.

Conclusion

ParkerVision’s 2025 results show meaningful progress in narrowing losses and improving its balance sheet through strategic capital raises. However, the lack of licensing revenue, continued legal uncertainties, and shareholder dilution events remain key concerns. Investors should closely monitor legal developments and the company’s ability to generate revenue from its intellectual property portfolio, as these could be significant catalysts for future share price movements.


Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Investors should consult the company’s official filings and their financial advisors before making investment decisions. The author holds no position in ParkerVision, Inc. and makes no representation or warranty as to the accuracy or completeness of the information contained herein. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

View PARKERVISION INC Historical chart here



Sotera Health Company Files Form 8-K with SEC Detailing Company Information and Compliance Data

Sotera Health Co. 8-K Filing: Key Investor Updates – March 2...

Laser Photonics Closes $1.5 Million Warrant Exercise; Issues New Warrants at Reduced Price for Growth Funding 1

Laser Photonics Announces Warrant Exercise and \$1.5 Million...

ORIC Pharmaceuticals 2025 Annual Report: Overcoming Cancer Resistance, Pipeline Overview, and Business Strategy

ORIC Pharmaceuticals, Inc. 2025 Annual Report - Detailed Inv...

   Ad